These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24171469)

  • 1. Structure-activity relationship of imidazopyridinium analogues as antagonists of neuropeptide s receptor.
    Patnaik S; Marugan JJ; Liu K; Zheng W; Southall N; Dehdashti SJ; Thorsell A; Heilig M; Bell L; Zook M; Eskay B; Brimacombe KR; Austin CP
    J Med Chem; 2013 Nov; 56(22):9045-56. PubMed ID: 24171469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tricyclic imidazole antagonists of the Neuropeptide S Receptor.
    Trotter BW; Nanda KK; Manley PJ; Uebele VN; Condra CL; Gotter AL; Menzel K; Henault M; Stocco R; Renger JJ; Hartman GD; Bilodeau MT
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4704-8. PubMed ID: 20615693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of neuropeptide S antagonists: structure-activity relationship studies, X-ray crystallography, and in vivo evaluation.
    Hassler C; Zhang Y; Gilmour B; Graf T; Fennell T; Snyder R; Deschamps JR; Reinscheid RK; Garau C; Runyon SP
    ACS Chem Neurosci; 2014 Aug; 5(8):731-44. PubMed ID: 24964000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropeptides and neuropeptide receptors: drug targets, and peptide and non-peptide ligands: a tribute to Prof. Dieter Seebach.
    Hoyer D; Bartfai T
    Chem Biodivers; 2012 Nov; 9(11):2367-87. PubMed ID: 23161624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists.
    Gore VK; Ma VV; Tamir R; Gavva NR; Treanor JJ; Norman MH
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5825-30. PubMed ID: 17851073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization of the mouse NPFF2 receptor.
    Talmont F; Moulédous L; Piedra-Garcia L; Schmitt M; Bihel F; Bourguignon JJ; Zajac JM; Mollereau C
    Peptides; 2010 Feb; 31(2):215-20. PubMed ID: 19944730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel brain penetrant NPS receptor antagonist, NCGC00185684, blocks alcohol-induced ERK-phosphorylation in the central amygdala and decreases operant alcohol self-administration in rats.
    Thorsell A; Tapocik JD; Liu K; Zook M; Bell L; Flanigan M; Patnaik S; Marugan J; Damadzic R; Dehdashti SJ; Schwandt ML; Southall N; Austin CP; Eskay R; Ciccocioppo R; Zheng W; Heilig M
    J Neurosci; 2013 Jun; 33(24):10132-42. PubMed ID: 23761908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.
    Coleman PJ; Cox CD; Roecker AJ
    Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor.
    Bailey JM; Scott JS; Basilla JB; Bolton VJ; Boyfield I; Evans DG; Fleury E; Heightman TD; Jarvie EM; Lawless K; Matthews KL; McKay F; Mok H; Muir A; Orlek BS; Sanger GJ; Stemp G; Stevens AJ; Thompson M; Ward J; Vaidya K; Westaway SM
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6452-8. PubMed ID: 19804969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.
    Lange JH; van Stuivenberg HH; Coolen HK; Adolfs TJ; McCreary AC; Keizer HG; Wals HC; Veerman W; Borst AJ; de Looff W; Verveer PC; Kruse CG
    J Med Chem; 2005 Mar; 48(6):1823-38. PubMed ID: 15771428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.
    Cox CD; Breslin MJ; Whitman DB; Schreier JD; McGaughey GB; Bogusky MJ; Roecker AJ; Mercer SP; Bednar RA; Lemaire W; Bruno JG; Reiss DR; Harrell CM; Murphy KL; Garson SL; Doran SM; Prueksaritanont T; Anderson WB; Tang C; Roller S; Cabalu TD; Cui D; Hartman GD; Young SD; Koblan KS; Winrow CJ; Renger JJ; Coleman PJ
    J Med Chem; 2010 Jul; 53(14):5320-32. PubMed ID: 20565075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.
    Malherbe P; Borroni E; Gobbi L; Knust H; Nettekoven M; Pinard E; Roche O; Rogers-Evans M; Wettstein JG; Moreau JL
    Br J Pharmacol; 2009 Apr; 156(8):1326-41. PubMed ID: 19751316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist.
    Winrow CJ; Gotter AL; Cox CD; Doran SM; Tannenbaum PL; Breslin MJ; Garson SL; Fox SV; Harrell CM; Stevens J; Reiss DR; Cui D; Coleman PJ; Renger JJ
    J Neurogenet; 2011 Mar; 25(1-2):52-61. PubMed ID: 21473737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a new class of macrocyclic antagonists to the human motilin receptor.
    Marsault E; Hoveyda HR; Peterson ML; Saint-Louis C; Landry A; Vézina M; Ouellet L; Wang Z; Ramaseshan M; Beaubien S; Benakli K; Beauchemin S; Déziel R; Peeters T; Fraser GL
    J Med Chem; 2006 Nov; 49(24):7190-7. PubMed ID: 17125271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Activity Relationship Studies of the Natural Product G
    Xiong XF; Zhang H; Boesgaard MW; Underwood CR; Bräuner-Osborne H; Strømgaard K
    ChemMedChem; 2019 Apr; 14(8):865-870. PubMed ID: 30790465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Activity Relationship Studies on Oxazolo[3,4-
    Albanese V; Ruzza C; Marzola E; Bernardi T; Fabbri M; Fantinati A; Trapella C; Reinscheid RK; Ferrari F; Sturaro C; Calò G; Amendola G; Cosconati S; Pacifico S; Guerrini R; Preti D
    J Med Chem; 2021 Apr; 64(7):4089-4108. PubMed ID: 33733768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Affinity Relationships and Structure-Kinetic Relationships of 1,2-Diarylimidazol-4-carboxamide Derivatives as Human Cannabinoid 1 Receptor Antagonists.
    Xia L; de Vries H; Lenselink EB; Louvel J; Waring MJ; Cheng L; Pahlén S; Petersson MJ; Schell P; Olsson RI; Heitman LH; Sheppard RJ; IJzerman AP
    J Med Chem; 2017 Dec; 60(23):9545-9564. PubMed ID: 29111736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.
    Di Fabio R; Pellacani A; Faedo S; Roth A; Piccoli L; Gerrard P; Porter RA; Johnson CN; Thewlis K; Donati D; Stasi L; Spada S; Stemp G; Nash D; Branch C; Kindon L; Massagrande M; Poffe A; Braggio S; Chiarparin E; Marchioro C; Ratti E; Corsi M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5562-7. PubMed ID: 21831639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional differences between NPFF1 and NPFF2 receptor coupling: high intrinsic activities of RFamide-related peptides on stimulation of [35S]GTPgammaS binding.
    Gouardères C; Mazarguil H; Mollereau C; Chartrel N; Leprince J; Vaudry H; Zajac JM
    Neuropharmacology; 2007 Feb; 52(2):376-86. PubMed ID: 17011599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.